Cargando…

Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice

Pseudomonas aeruginosa is a common cause of hospital-acquired infections, including central line-associated bloodstream infections and ventilator-associated pneumonia. Unfortunately, effective control of these infections can be difficult, in part due to the prevalence of multi-drug resistant strains...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jason, Mateu-Borrás, Margalida, Monroe, Hunter L., Sen-Kilic, Emel, Miller, Sarah Jo, Dublin, Spencer R., Huckaby, Annalisa B., Yang, Evita, Pyles, Gage M., Nunley, Mason A., Chapman, Josh A., Amin, Md Shahrier, Damron, F. Heath, Barbier, Mariette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326049/
https://www.ncbi.nlm.nih.gov/pubmed/37424774
http://dx.doi.org/10.3389/fcimb.2023.1191806
_version_ 1785069346238758912
author Kang, Jason
Mateu-Borrás, Margalida
Monroe, Hunter L.
Sen-Kilic, Emel
Miller, Sarah Jo
Dublin, Spencer R.
Huckaby, Annalisa B.
Yang, Evita
Pyles, Gage M.
Nunley, Mason A.
Chapman, Josh A.
Amin, Md Shahrier
Damron, F. Heath
Barbier, Mariette
author_facet Kang, Jason
Mateu-Borrás, Margalida
Monroe, Hunter L.
Sen-Kilic, Emel
Miller, Sarah Jo
Dublin, Spencer R.
Huckaby, Annalisa B.
Yang, Evita
Pyles, Gage M.
Nunley, Mason A.
Chapman, Josh A.
Amin, Md Shahrier
Damron, F. Heath
Barbier, Mariette
author_sort Kang, Jason
collection PubMed
description Pseudomonas aeruginosa is a common cause of hospital-acquired infections, including central line-associated bloodstream infections and ventilator-associated pneumonia. Unfortunately, effective control of these infections can be difficult, in part due to the prevalence of multi-drug resistant strains of P. aeruginosa. There remains a need for novel therapeutic interventions against P. aeruginosa, and the use of monoclonal antibodies (mAb) is a promising alternative strategy to current standard of care treatments such as antibiotics. To develop mAbs against P. aeruginosa, we utilized ammonium metavanadate, which induces cell envelope stress responses and upregulates polysaccharide expression. Mice were immunized with P. aeruginosa grown with ammonium metavanadate and we developed two IgG2b mAbs, WVDC-0357 and WVDC-0496, directed against the O-antigen lipopolysaccharide of P. aeruginosa. Functional assays revealed that WVDC-0357 and WVDC-0496 directly reduced the viability of P. aeruginosa and mediated bacterial agglutination. In a lethal sepsis model of infection, prophylactic treatment of mice with WVDC-0357 and WVDC-0496 at doses as low as 15 mg/kg conferred 100% survival against challenge. In both sepsis and acute pneumonia models of infection, treatment with WVDC-0357 and WVDC-0496 significantly reduced bacterial burden and inflammatory cytokine production post-challenge. Furthermore, histopathological examination of the lungs revealed that WVDC-0357 and WVDC-0496 reduced inflammatory cell infiltration. Overall, our results indicate that mAbs directed against lipopolysaccharide are a promising therapy for the treatment and prevention of P. aeruginosa infections.
format Online
Article
Text
id pubmed-10326049
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103260492023-07-08 Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice Kang, Jason Mateu-Borrás, Margalida Monroe, Hunter L. Sen-Kilic, Emel Miller, Sarah Jo Dublin, Spencer R. Huckaby, Annalisa B. Yang, Evita Pyles, Gage M. Nunley, Mason A. Chapman, Josh A. Amin, Md Shahrier Damron, F. Heath Barbier, Mariette Front Cell Infect Microbiol Cellular and Infection Microbiology Pseudomonas aeruginosa is a common cause of hospital-acquired infections, including central line-associated bloodstream infections and ventilator-associated pneumonia. Unfortunately, effective control of these infections can be difficult, in part due to the prevalence of multi-drug resistant strains of P. aeruginosa. There remains a need for novel therapeutic interventions against P. aeruginosa, and the use of monoclonal antibodies (mAb) is a promising alternative strategy to current standard of care treatments such as antibiotics. To develop mAbs against P. aeruginosa, we utilized ammonium metavanadate, which induces cell envelope stress responses and upregulates polysaccharide expression. Mice were immunized with P. aeruginosa grown with ammonium metavanadate and we developed two IgG2b mAbs, WVDC-0357 and WVDC-0496, directed against the O-antigen lipopolysaccharide of P. aeruginosa. Functional assays revealed that WVDC-0357 and WVDC-0496 directly reduced the viability of P. aeruginosa and mediated bacterial agglutination. In a lethal sepsis model of infection, prophylactic treatment of mice with WVDC-0357 and WVDC-0496 at doses as low as 15 mg/kg conferred 100% survival against challenge. In both sepsis and acute pneumonia models of infection, treatment with WVDC-0357 and WVDC-0496 significantly reduced bacterial burden and inflammatory cytokine production post-challenge. Furthermore, histopathological examination of the lungs revealed that WVDC-0357 and WVDC-0496 reduced inflammatory cell infiltration. Overall, our results indicate that mAbs directed against lipopolysaccharide are a promising therapy for the treatment and prevention of P. aeruginosa infections. Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10326049/ /pubmed/37424774 http://dx.doi.org/10.3389/fcimb.2023.1191806 Text en Copyright © 2023 Kang, Mateu-Borrás, Monroe, Sen-Kilic, Miller, Dublin, Huckaby, Yang, Pyles, Nunley, Chapman, Amin, Damron and Barbier https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Kang, Jason
Mateu-Borrás, Margalida
Monroe, Hunter L.
Sen-Kilic, Emel
Miller, Sarah Jo
Dublin, Spencer R.
Huckaby, Annalisa B.
Yang, Evita
Pyles, Gage M.
Nunley, Mason A.
Chapman, Josh A.
Amin, Md Shahrier
Damron, F. Heath
Barbier, Mariette
Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice
title Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice
title_full Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice
title_fullStr Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice
title_full_unstemmed Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice
title_short Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice
title_sort monoclonal antibodies against lipopolysaccharide protect against pseudomonas aeruginosa challenge in mice
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326049/
https://www.ncbi.nlm.nih.gov/pubmed/37424774
http://dx.doi.org/10.3389/fcimb.2023.1191806
work_keys_str_mv AT kangjason monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT mateuborrasmargalida monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT monroehunterl monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT senkilicemel monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT millersarahjo monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT dublinspencerr monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT huckabyannalisab monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT yangevita monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT pylesgagem monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT nunleymasona monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT chapmanjosha monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT aminmdshahrier monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT damronfheath monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice
AT barbiermariette monoclonalantibodiesagainstlipopolysaccharideprotectagainstpseudomonasaeruginosachallengeinmice